DNA Methylation: from Biology to Disease
Cancerdip is a European research initiative funded by the 7th Framework Programme for Research and Technological Development of the European Commission (FP7).
The international team of experts involved in CANCERDIP consortium represent complementing scientific disciplines that joint forces to decipher the language of the epigenetic control that lead to human cancer. It is well established that tumor suppressor genes undergo epigenetic inactivation in cancer in a tumour-type specific fashion, however epigenomic approaches to cover the entire range of genes affected by epigenetic inactivation need to be used. The identification of the methylation patterns in different tumour types, as well as the identification of the epigenetic machinery involved in the establishment of these aberrant patterns, is key not only to understand the pathway that leads to cancer but also to generate markers with invaluable clinical value. A great deal of the technology used in this project is based in the MeDIP (Methyl-DNA Immuno-Precipitation). Scientists with outstanding reputation in their respective fields have been gathered to improve the knowledge on epigenetics and its involvement in human cancer. Furthermore, they are going to design, built and validate a MeDIP technology based platform to understand the epigenetic events that occur in human cancer and to help in the clinical management of human neoplasia. The team is form by a multidisciplinary and highly-competitive community of European scientists very well suited to this task as they bring together a set of skills that complements the objectives in this research area.
|Full project Title:||The Use of Methylated DNA Immunoprecipitation (MeDIP) in Cancer for better Clinical Management|
|Project Type:||Collaborative Project, Small or medium-scale focused research project|
|Number of partners:||6|
|Coordinator:||Dr Manel Esteller, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona|